Key Takeaways
- Revenue crosses ₹500 Cr milestone: FY26 revenue exceeded ₹500 crores, with EBITDA surging 214% YoY on better product mix and operating leverage.
- Electrolyte Salts explode 1,378% YoY: The segment is now a material contributor, guided to 8–10% of FY27 revenue, driven by steady volume ramp-up in energy storage applications.
- FY27 guidance set at ~25% revenue growth: Management targets 20–25% top-line growth and 20–22% EBITDA margins, absorbing geopolitical cost pressures through customer cooperation and plant efficiency.
- Jolva breaks ground this quarter: The next growth phase, with Phase 1 revenue potential of ₹400–500 Cr, targets commercial production in early 2028, while Dahej can scale to ₹850–900 Cr with minor capex.
- What to watch next quarter: Dispatch of the first commercial-scale semiconductor batch, the trajectory of Electrolyte Salts quarterly run-rate, and whether Euro 7-linked SDA demand begins its uptick around July–August.
Financial Performance & Cost Environment
- EBITDA leap: 214% YoY and 10% QoQ growth was primarily supported by better product mix and improved operating leverage as the new Dahej block ramped up.
- Geopolitical cost pressure: Rising fuel, packing material, and key raw material costs (crude-origin and ammonia-linked) pushed up input prices, while freight rates also increased. Raw material availability continued almost smoothly except for some delays.
- Cost pass-through mechanics: Most major customers shared the impact of rising costs; the company honored all open orders and gradually implemented increased prices on new orders, with management noting customers are cooperating though not absorbing at 100%.
- Tax rate spike is temporary: A high quarterly tax rate resulted from losing 10AA benefits this year plus heavy capex (~₹100 Cr) increasing deferred tax; effective rates will come down as book and tax depreciation synchronize.
- Dividend defended: The company retains 80% of earnings and distributes about 10% of profit as dividend, calling the policy "pretty fair," though the rationale was questioned given increased short-term borrowings and finance costs.
Pillai: "Not actually because the prices are going up due to the geopolitical situation and other things. But gradually, it is being absorbed by our customers. Our customers are cooperating, although they are not being absorbed at 100% level, but probably we believe that it will gradually be absorbed. And we don't intend to change anything on our guidance in that matter."
Electrolyte Salts: The New Growth Engine
- Explosive quarterly growth: The segment delivered 865% QoQ and 1,378% YoY growth, driven by increasing consumption in energy storage applications as a customer utilizing electrolytes for energy storage devices showed a steady volume ramp-up.
- FY27 revenue contribution: Expected to reach 8–10% of overall revenue, making it a relevant contributor, with management projecting roughly 4x the current quarterly revenue on a yearly basis.
- Run-rate sustainability: Management described growth as sustainable, expecting revenue "somewhere around the same point in all the quarters" while cautioning it "may not be apple-to-apple every quarter."
- Hybrid battery application: Work with a customer engaged in hybrid battery applications is progressing well, with commercial business beginning in Q3 of the current year and a gradual ramp-up to full scale by 2028 when the actual vehicle launch occurs in mid-2028.
SDA: Steady Demand, Euro 7 Catalyst Ahead
- Demand stability: Demand is pretty stable with regular orders being punched in by customers; the only risk is demand volatility of the kind seen post-COVID with inventory pile-up and crash, but things are now normal.
- Market structure advantage: A duopoly with Sarchem at ~85% and Tatva at ~15% creates a non-price-sensitive environment where, once a product is approved for a specific vehicle variant, there is no space to change suppliers. Customers keep both suppliers engaged, typically giving no more than 70% volume to one.
- Raw material pass-through: When Iran-related issues caused raw material prices to shoot up, customers readily agreed to apply existing formulas and revised prices for new purchase orders, making this a low-risk business on the cost side.
- Euro 7 timing advantage: Unlike Euro 6, where Tatva was a very late entrant, the company is well in time with a foot in the door from the beginning for Euro 7, and expects to gradually see market share rise due to a pricing advantage over the US manufacturer.
- Growth trajectory: SDA is guided to grow at least 20% in the current financial year, reaching ₹250–300 Cr, with the Euro 7 uptick expected to start showing in numbers around July or August.
Chintan Shah: "customers also know that there are only two suppliers for this product. So, they always try to keep a balance. Maybe if I say I get most of the share, then I mean I may be getting 70% of the volume. You will never get more from any particular customer for any particular product because that is how they want to keep both of us engaged in this business."
PASC & Agro Intermediates: Near-Term Drag, Structural Promise
- PASC decline was operational, not demand-driven: The 24% sequential decline was not due to lack of orders but because trial production started in the new facility in January, commercialized in February, and post-commercialization challenges in streamlining production caused dispatch delays; these are now overcome.
- Order visibility intact: Good visibility extends till the end of the current calendar year, and the product is expected to continue contributing next year as well.
- Long-term scale ambition: PASC will become much larger than SDA once the Jolva plant becomes operational, with the dedicated facility using a new technology fully developed in-house for which no single patent or process has been filed by this route of chemistry.
- Agro intermediates ramping: Both the photochlorination product and the larger product faced challenges that have been gradually sorted out; production is now smoother with consistent dispatches, and no demand challenge is seen for calendar year 2026.
Chintan Shah: "this is being done by a new technology, which has been fully developed in-house. And we have not seen any single patent or process filed by this route of chemistry. So it is something exceptional that our team has achieved, and we are really proud of that."
New Verticals: Pharma & Semiconductor
- Pharma commercialization begins: All validations of pharma products have been successfully completed, actual commercialization has begun with a couple of orders executed for the first product, and dispatches have already started. FY27 pharma revenue is guided at ₹70–75 Cr as a completely new add-on.
- Semiconductor milestone achieved: Plant-scale trials for the first product were completed successfully, and the first commercial-scale batch (not pilot) will be dispatched in the current quarter (Q1 FY27).
- Semiconductor timeline is patient: Final commercialization is expected around end of 2028 to early 2029, with scale-up remaining gradual. Management describes the entry barriers as even worse than SDA, demanding years of patience for an opportunity.
- Second semiconductor application: A hybrid battery application will go online by November or December of this calendar year, with gradual ramp-up to full scale by 2028 when the actual vehicle launch happens in mid-2028.
Chintan Shah: "if SDA, I have been saying all these years is a very difficult entry barrier, most difficult part to get an entry into this. You wait for the opportunity for years. This particular segment is even worse than that. Demands a lot of patience."
Capacity & Capex: Dahej Now, Jolva Next
- Dahej fully operational: The new production block at Dahej is now working very smoothly on a commercial scale and can scale to ₹850–900 Cr revenue with minor bottleneck-removal capex, though full potential will be reached in FY28, not the current financial year.
- Jolva groundbreaking imminent: Preparatory work has progressed further, with groundbreaking expected this quarter (Q1 FY27); design-stage enhancements have been identified to improve long-term scalability and operational efficiency.
- Jolva Phase 1 economics: Revenue potential of ₹400–500 Cr, with commercial production targeted in the first couple of months of 2028 (18–20 months from the planning stage), bringing the next phase of growth from FY28-29.
- Peak revenue correction: When an analyst computed peak potential revenue at ~₹700 Cr from current capacity, management corrected the figure upward to ₹850–900 Cr.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | ~25% (range: 20–25%, staying conservative due to geopolitical uncertainties) | FY27 |
| EBITDA margin | 20% to 22% on a realistic basis | FY27 |
| Electrolyte Salts revenue contribution | 8% to 10% of overall revenue | FY27 |
| SDA revenue | At least 20% growth, reaching ₹250–300 Cr | FY27 |
| Pharma revenue | ₹70–75 Cr, completely new add-on | FY27 |
| Jolva groundbreaking | Break ground within 60 days (mid-July) | Q1 FY27 |
| Jolva commercial production | Production start, 18–20 months from planning stage | Jan–Mar 2028 |
| Semiconductor first dispatch | First commercial-scale batch dispatched | Q1 FY27 |
| Semiconductor final commercialization | Scale-up gradual | End of 2028 to early 2029 |
| Hybrid battery commercial start | Go online | Nov–Dec 2026 |
| Hybrid battery full scale | Ramp-up to full scale when vehicle launches mid-2028 | Late 2027 to early 2028 |
| Dahej full potential | Reach ₹850–900 Cr revenue capacity | FY28 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Operating revenue | ₹134.1 cr, +24% YoY and +2% QoQ |
| EBITDA | ₹28.1 cr, +214% YoY and +10% QoQ |
| EBITDA margin | 21.0%, supported by better product mix and improved operating leverage |
| Phase Transfer Catalyst revenue | ₹31.1 cr, -20% YoY and +11% QoQ |
| Electrolyte Salts revenue | ₹13.1 cr, +1,378% YoY and +865% QoQ |
| Pharma and Agro Intermediates and Specialty Chemicals revenue | ₹35.8 cr, +10% YoY and -24% QoQ; sequential decline due to production ramp-up challenges at new facility |
| Structure Directing Agents revenue | ₹52.5 cr, +52% YoY and -2% QoQ |
| Full-year FY26 revenue | In excess of ₹500 cr, milestone year marking 30 years of operations |
| Revenue growth guidance for FY27 | ~25% |
| EBITDA margin guidance for FY27 | 20% to 22% |
| Electrolyte Salts expected revenue contribution in FY27 | 8% to 10% of total revenue |
| SDA revenue guidance for FY27 | ₹250 cr to ₹300 cr, at least 20% growth |
| Pharma revenue expectation for FY27 | ₹70 cr to ₹75 cr, completely new add-on from three products commercializing |
| Current capacity utilization | 80% to 85% |
| Current facility peak revenue potential | ₹850 cr to ₹900 cr, with minor debottlenecking capex of ₹10 cr to ₹12 cr per year |
| Jolva greenfield Phase 1 revenue potential | ₹400 cr to ₹500 cr; groundbreaking in Q1 FY27, commercial production early 2028 |
| Jolva project total capex | ₹250 cr to ₹270 cr, with ₹100 cr in FY27 and ₹175 cr in FY28 |
| Effective tax rate | ~26% annual; Q4 at 38% due to carryforward losses and deferred tax on heavy capex |
| Semiconductor chemicals impurity levels achieved | Below 1 part per billion, in the 1,000 parts per trillion range |